Development of Rifapentine-Loaded PLGA-Based Nanoparticles: In vitro Characterisation and in vivo Study in Mice
Authors:
Open Access
- 1 October 2020
- journal article
- research article
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 15, 7491-7507
Abstract
Background: Tuberculosis (TB) is a leading cause of death amongst infectious diseases. The poor response to antitubercular agents necessitates the long-term use of high drug doses, resulting in low patient compliance, which is the main reason for chemotherapy failure and contributes to the development of multidrug-resistant TB. Patient non-compliance has been a major obstacle in the successful management of TB. The aim of this work was to develop and characterise rifapentine (RPT)-loaded PLGA-based nanoparticles (NPs) for reducing dosing frequency. Methods: RPT-loaded PLGA and PLGA–PEG NPs were prepared using premix membrane homogenisation combined with solvent evaporation method. The resulting NPs were characterised in terms of physicochemical characteristics, toxicity, cellular uptake and antitubercular activity. NPs were further evaluated for pharmacokinetic and biodistribution studies in mice. Results: The resulting NPs showed suitable and safe physicochemical characteristics and could be taken up by macrophages. RPT-loaded NPs were more effective against Mycobacterium tuberculosis than free RPT. In vivo studies revealed that NPs could improve pharmacokinetic parameters, particularly for RPT/PLGA–PEG NPs. Moreover, both formulations had no toxicity to the organs of mice and could reduce hepatotoxicity. Conclusion: The application of PLGA-based NPs as sustained-release delivery vehicles for RPT could prolong drug release, modify pharmacokinetics, increase antitubercular activity and diminish toxicity, thereby allowing low dosage and frequency.Keywords
This publication has 58 references indexed in Scilit:
- Optimization of Rifapentine-Loaded Lipid Nanoparticles Using a Quality-by-Design StrategyPharmaceutics, 2020
- A Novel Approach in Treatment of Tuberculosis by Targeting Drugs to Infected Macrophages Using Biodegradable NanoparticlesApplied Biochemistry and Biotechnology, 2018
- Preparation of Drug-Loaded PLGA-PEG Nanoparticles by Membrane-Assisted NanoprecipitationPharmaceutical Research, 2017
- Effect of poly(ethylene glycol) content and formulation parameters on particulate properties and intraperitoneal delivery of insulin from PLGA nanoparticles prepared using the double-emulsion evaporation procedurePharmaceutical Development and Technology, 2017
- PLGA nanoparticles for the oral delivery of nuciferine: preparation, physicochemical characterization and in vitro/in vivo studiesDrug Delivery, 2017
- Nanobead-based interventions for the treatment and prevention of tuberculosisNature Reviews Microbiology, 2010
- PLGA Nanoparticles for Oral Delivery of Hydrophobic Drugs: Influence of Organic Solvent on Nanoparticle Formation and Release Behavior In Vitro and In Vivo Using Estradiol as a Model DrugJournal of Pharmaceutical Sciences, 2008
- Preparation and antibacterial activity evaluation of rifampicin-loaded poly lactide-co-glycolide nanoparticlesNanomedicine: Nanotechnology, Biology and Medicine, 2007
- Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticlesInternational Journal of Pharmaceutics, 2006
- Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosisJournal of Antimicrobial Chemotherapy, 2003